FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2574536037> ?p ?o ?g. }

• W2574536037 abstract "Abstract Abstract 641 Several mathematical models and ex-vivo examinations suggested that imatinib (IM) therapy does not eradicate BCR-ABL-positive leukemia stem cells (LSCs). We investigated 47 CML-chronic phase cases using methods previously reported (Jamieson et al., N Engl J Med, 2004. and Abe et al., Int J Hematol, 2008) with FACSAria™ and quantitative RT-PCR of BCR-ABL among each sorted population; total mononuclear cells, HSC/Thy-1+, HSC/Thy-1–, common myeloid progenitors (CMP), granulocyte macrophage progenitors (GMP) and megakaryocyte erythroid progenitors (MEP). In optimal responders to IM therapy, BCR-ABL transcripts in the HSC populations (HSC/Thy-1+ and HSC/Thy-1–) tended to be more retentive than other populations, while a gradual reduction was observed during the first 12 months in all populations. Moreover, the discrepancy of minimum residual diseases (MRD) between HSC and other populations became greater (about 2 log difference) in patients after longer IM therapy. We also prospectively investigated BCR-ABL transcripts in each population of 27 IM-resistant or -intolerant cases during treatment with the second-generation of ABL-tyrosine kinase inhibitors (2nd TKIs), dasatinib or nilotinib. Treatment with each inhibitor induced more rapid reduction of BCR-ABL transcripts even in the HSC population (CD34+CD38–) during the first 6 months for IM-intolerant cases, and there was no statistical difference of MRD among each population in optimal responders to 2nd TKI therapy. In order to examine mechanisms of Ph+ LSC resistance to IM, Ph+ ALL patient cells were serially xenotransplanted into immunodeficient NOD/SCID/IL2rγnull (NOG) mice and cells derived from leukemic NOG mice were then co-cultured with S17-stromal cells using previously reported methods (Minami et al., PNAS, 2008). Despite complete dephosphorylations of BCR-ABL and its substrate CrkL, slow-cycling (Hoechst-33342low/Pyronin-Ylow) CD34+ cells were insensitive to IM, which indicated that addiction of BCR-ABL activity is lower for survival in such quiescent cells. On the other hand, treatment with lower doses of 2nd TKIs induced not only growth inhibition but also substantial cell death including slow-cycling CD34+ population. More detailed biomarkers during pro-apoptotic status by 2nd TKI treatment are also under investigation. From comprehensive drug screening of small compounds in this co-culturing system, we also found several candidates involved with survival pathways in the cells. These results imply that 2nd TKI therapy can be a more promising approach than IM treatment for early reduction of Ph+ LSCs. Disclosures: Naoe: Kyowa-Hakko Kirin.: Research Funding; Dainipponn-Sumitomo Pharma.: Research Funding; Chugai Pharma.: Research Funding; Novartis Pharma.: Research Funding; Zenyaku-Kogyo: Research Funding; Otsuka Pharma.: Research Funding." @default.
• W2574536037 created "2017-01-26" @default.
• W2574536037 creator A5008097340 @default.
• W2574536037 creator A5018968800 @default.
• W2574536037 creator A5019005679 @default.
• W2574536037 creator A5030193536 @default.
• W2574536037 creator A5044099774 @default.
• W2574536037 creator A5048075263 @default.
• W2574536037 creator A5069675532 @default.
• W2574536037 creator A5074752282 @default.
• W2574536037 creator A5084655190 @default.
• W2574536037 creator A5086056792 @default.
• W2574536037 date "2011-11-18" @default.
• W2574536037 modified "2023-09-27" @default.
• W2574536037 title "Retention of Slow-Cycling CD34+ cells During Imatinib Treatment and Rapid Decline After 2nd ABL-TKI Treatment in Ph+ Leukemia Cells" @default.
• W2574536037 doi "https://doi.org/10.1182/blood.v118.21.641.641" @default.
• W2574536037 hasPublicationYear "2011" @default.
• W2574536037 type Work @default.
• W2574536037 sameAs 2574536037 @default.
• W2574536037 citedByCount "0" @default.
• W2574536037 crossrefType "journal-article" @default.
• W2574536037 hasAuthorship W2574536037A5008097340 @default.
• W2574536037 hasAuthorship W2574536037A5018968800 @default.
• W2574536037 hasAuthorship W2574536037A5019005679 @default.
• W2574536037 hasAuthorship W2574536037A5030193536 @default.
• W2574536037 hasAuthorship W2574536037A5044099774 @default.
• W2574536037 hasAuthorship W2574536037A5048075263 @default.
• W2574536037 hasAuthorship W2574536037A5069675532 @default.
• W2574536037 hasAuthorship W2574536037A5074752282 @default.
• W2574536037 hasAuthorship W2574536037A5084655190 @default.
• W2574536037 hasAuthorship W2574536037A5086056792 @default.
• W2574536037 hasConcept C10205521 @default.
• W2574536037 hasConcept C109159458 @default.
• W2574536037 hasConcept C126322002 @default.
• W2574536037 hasConcept C150903083 @default.
• W2574536037 hasConcept C159912055 @default.
• W2574536037 hasConcept C170493617 @default.
• W2574536037 hasConcept C201750760 @default.
• W2574536037 hasConcept C203014093 @default.
• W2574536037 hasConcept C207001950 @default.
• W2574536037 hasConcept C26291073 @default.
• W2574536037 hasConcept C2777413986 @default.
• W2574536037 hasConcept C2777583451 @default.
• W2574536037 hasConcept C2778729363 @default.
• W2574536037 hasConcept C2779536868 @default.
• W2574536037 hasConcept C2779705218 @default.
• W2574536037 hasConcept C28328180 @default.
• W2574536037 hasConcept C2908647359 @default.
• W2574536037 hasConcept C3019892230 @default.
• W2574536037 hasConcept C42362537 @default.
• W2574536037 hasConcept C502942594 @default.
• W2574536037 hasConcept C54355233 @default.
• W2574536037 hasConcept C71924100 @default.
• W2574536037 hasConcept C86803240 @default.
• W2574536037 hasConcept C99454951 @default.
• W2574536037 hasConceptScore W2574536037C10205521 @default.
• W2574536037 hasConceptScore W2574536037C109159458 @default.
• W2574536037 hasConceptScore W2574536037C126322002 @default.
• W2574536037 hasConceptScore W2574536037C150903083 @default.
• W2574536037 hasConceptScore W2574536037C159912055 @default.
• W2574536037 hasConceptScore W2574536037C170493617 @default.
• W2574536037 hasConceptScore W2574536037C201750760 @default.
• W2574536037 hasConceptScore W2574536037C203014093 @default.
• W2574536037 hasConceptScore W2574536037C207001950 @default.
• W2574536037 hasConceptScore W2574536037C26291073 @default.
• W2574536037 hasConceptScore W2574536037C2777413986 @default.
• W2574536037 hasConceptScore W2574536037C2777583451 @default.
• W2574536037 hasConceptScore W2574536037C2778729363 @default.
• W2574536037 hasConceptScore W2574536037C2779536868 @default.
• W2574536037 hasConceptScore W2574536037C2779705218 @default.
• W2574536037 hasConceptScore W2574536037C28328180 @default.
• W2574536037 hasConceptScore W2574536037C2908647359 @default.
• W2574536037 hasConceptScore W2574536037C3019892230 @default.
• W2574536037 hasConceptScore W2574536037C42362537 @default.
• W2574536037 hasConceptScore W2574536037C502942594 @default.
• W2574536037 hasConceptScore W2574536037C54355233 @default.
• W2574536037 hasConceptScore W2574536037C71924100 @default.
• W2574536037 hasConceptScore W2574536037C86803240 @default.
• W2574536037 hasConceptScore W2574536037C99454951 @default.
• W2574536037 hasLocation W25745360371 @default.
• W2574536037 hasOpenAccess W2574536037 @default.
• W2574536037 hasPrimaryLocation W25745360371 @default.
• W2574536037 hasRelatedWork W1980792863 @default.
• W2574536037 hasRelatedWork W1996346809 @default.
• W2574536037 hasRelatedWork W2025480404 @default.
• W2574536037 hasRelatedWork W2134288099 @default.
• W2574536037 hasRelatedWork W2512064655 @default.
• W2574536037 hasRelatedWork W2535211482 @default.
• W2574536037 hasRelatedWork W2547251167 @default.
• W2574536037 hasRelatedWork W2549347178 @default.
• W2574536037 hasRelatedWork W2557014216 @default.
• W2574536037 hasRelatedWork W2558408744 @default.
• W2574536037 hasRelatedWork W2559877690 @default.
• W2574536037 hasRelatedWork W2573169346 @default.
• W2574536037 hasRelatedWork W2573705747 @default.
• W2574536037 hasRelatedWork W2581808590 @default.
• W2574536037 hasRelatedWork W2591022558 @default.
• W2574536037 hasRelatedWork W2979543376 @default.
• W2574536037 hasRelatedWork W2979656709 @default.
• W2574536037 hasRelatedWork W2979970416 @default.

• next